Drugs / NNC9733-0001
last change Nov 2025 re-read 3 minutes ago

NNC9733-0001

Developed for
type 2 diabetes mellitus
Investigated by
Novo Nordisk A/S

Trials 1

202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07270731 Nov 2025 → Mar 2028 expected type 2 diabetes mellitus Novo Nordisk A/S Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NNC9733-0001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07270731 ↗